Parul Patel

Learn More
—The proposed study offers an approach to incorporate the effect of surface roughness in the estimation of soil moisture from space without actually measuring surface roughness conditions on ground. It is required to acquire synthetic aperture radar data at low and high incidence angles, such that the soil moisture changes are negligible between the two(More)
AIMS To determine long-term efficacy of riboflavin/ultraviolet A corneal cross-linking (CXL). METHODS Thirty patients (30 eyes) who had undergone CXL following epithelial removal 4-6 years previously were examined. RESULTS At 1-year mean, spherical equivalent error (SEQ) increased by +0.72 dioptres (D) (p<0.002), corrected distance visual acuity (CDVA)(More)
This study evaluated dolutegravir pharmacokinetics (PK) in subjects with moderate hepatic impairment compared to matched, healthy controls. In this open‐label, parallel‐group study, eight adult subjects with moderate hepatic impairment (Child‐Pugh Score 7–9) and eight healthy subjects matched for gender, age, and body mass index received a single(More)
BACKGROUND Traditional first line regimens containing a non-nucleoside reverse transcriptase inhibitor or protease inhibitor may not be suitable for a subset of antiretroviral-naïve patients such as those with certain co-morbidities, women of child-bearing potential, and intolerability to components of standard first line therapy. This study was conducted(More)
Traditionally, fluoroscopic examinations such as enteroclysis, upper GI studies, and small bowel follow through exams have been the procedures of choice in evaluating inflammatory bowel disease (IBD) in pediatric populations. With the advent of multidetector computed tomography (MDCT), it has subsequently become a complementary examination in imaging(More)
A randomized, partial-blind, repeat-dose, 3-period crossover study (NCT02027454) assessed the effect of cabotegravir on QT interval in healthy subjects. To achieve a supratherapeutic dose, each subject received cabotegravir 150 mg (30 mg × 5 tablets) every 12 hours for a total of 3 doses over 2 days, matching placebo (every 12 hours) over 2 days, or a(More)
  • 1